1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24116
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGamucci, T.en
dc.contributor.authorParidaens, R.en
dc.contributor.authorHeinrich, B.en
dc.contributor.authorSchellens, J. H.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorVerweij, J.en
dc.contributor.authorSessa, C.en
dc.contributor.authorKaye, S.en
dc.contributor.authorRoelvink, M.en
dc.contributor.authorWanders, J.en
dc.contributor.authorHanauske, A.en
dc.date.accessioned2015-11-24T19:38:09Z-
dc.date.available2015-11-24T19:38:09Z-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24116-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents/adverse effects/*pharmacology/therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/pathologyen
dc.subjectCamptothecin/adverse effects/analogs & derivatives/*pharmacology/therapeutic useen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapy/pathologyen
dc.subjectColorectal Neoplasms/*drug therapy/pathologyen
dc.subjectDose-Response Relationship, Drugen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInfusions, Intravenousen
dc.subjectLung Neoplasms/*drug therapy/pathologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectTreatment Outcomeen
dc.titleActivity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10997805-
heal.identifier.secondaryhttp://annonc.oxfordjournals.org/content/11/7/793.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2000-
heal.abstractBACKGROUND: GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor activity and an acceptable toxicity profile. PATIENTS AND METHODS: Between April 1995 and November 1996, 67 eligible patients with pretreated breast cancer (25 patients) and chemo-naive colorectal (19 patients) and non-small-cell lung cancer (23 patients) were entered into three multicentric, non-randomized phase II trials. Treatment schedule consisted of intravenous GI1147211 administered at a dose of 1.2 mg/m2/day for five consecutive days every three weeks. RESULTS: Hematological toxicity was common with grade 3-4 neutropenia in 54% of patients and neutropenic fever together or not associated with infection in 14.5% of patients. Grade 3-4 thrombocytopenia and grade 2-4 anemia were observed in 20% and in 68% of patients, respectively. Non-hematological toxicity was generally mild to moderate and consisted mainly of gastrointestinal toxicity, asthenia and alopecia. A dose-escalation to 1.5 mg/m2/d was feasible in 17 (25%) patients. The antitumor activity of GI1147211 was moderate in breast cancer patients (3 partial responses (PRs), response rate (RR) 13%) and minimal in non-small cell lung cancer patients (2 PRs, RR 9%). No objective responses were obtained in colorectal patients. CONCLUSIONS: GI147211, at the dose and schedule employed in this study, showed an acceptable safety profile but a modest antitumor activity in the examined tumor types.en
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Gamucci-2000-Activity and toxicit.pdf499.67 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons